Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

@article{Damaj2013ResultsFA,
  title={Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.},
  author={Gandhi Damaj and R{\'e}my Gressin and Krimo Bouabdallah and Guillaume Cartron and Bachra Choufi and Emmanuel Gyan and Anne Banos and Arnaud Jaccard and Sophie Elizabeth Park and Olivier Tournilhac and Jean-Marc Schiano-de Collela and Laurent Voillat and Bertrand Joly and Steven Le Gouill and Alain Saad and Pascale Cony-Makhoul and J P Vilque and Laurence Sanhes and Aline Schmidt-Tanguy and Michael Bubenheim and Roch Houot and Momar Diouf and Jean-Pierre Marolleau and M V B{\'e}n{\'e} and Antoine Martin and Thierry Lamy},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 1},
  pages={104-10}
}
PURPOSE To determine the efficacy and safety of bendamustine as a single agent in refractory or relapsed T-cell lymphomas. PATIENTS AND METHODS Patients with histologically confirmed peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma who progressed after one or more lines of prior chemotherapy received bendamustine at 120 mg/m(2) per day on… CONTINUE READING